Navigation Links
Dr. Marschall S. Runge Elected to Lilly Board of Directors
Date:8/28/2013

INDIANAPOLIS, Aug. 28, 2013 /PRNewswire/ -- The Board of Directors of Eli Lilly and Company (NYSE: LLY) has elected Marschall S. Runge, M.D., Ph.D., as a new member, effective September 1, 2013.  Dr. Runge, 59, is the Executive Dean for the School of Medicine at the University of North Carolina at Chapel Hill (UNC). As a member of Lilly's board, Dr. Runge will serve on the Science and Technology Committee and the Public Policy and Compliance Committee.

"I am very pleased to welcome Marschall Runge to the Lilly board," said John Lechleiter, Ph.D., Lilly chairman, president and chief executive officer. "Dr. Runge brings to the Lilly board a broad background in health care, with extensive experience as a practicing physician, clinical researcher, and dean of a major academic medical institution. His appreciation of the importance of scientific research, coupled with his first-hand experience in patient care, will help Lilly deliver on its commitment to discover and develop innovative medicines that make a difference for patients in need."

In his role as Executive Dean for the UNC School of Medicine, Dr. Runge provides overall academic and clinical leadership for the School of Medicine and the UNC Health Care System. In addition to being the Chair of the Department of Medicine, Dr. Runge is also Principal Investigator and Director of the North Carolina Translational and Clinical Sciences (NC TraCS) Institute at UNC-Chapel Hill, where he has financial, human resource and strategic oversight responsibilities for the program. The NC TraCS Institute is one of 60 medical research institutions working together as part of a national consortium to improve the way biomedical research is conducted across the country and to reduce the time it takes for laboratory discoveries to become new treatments for patients.

An honors graduate of Vanderbilt University with a B.A. in Biology and a Ph.D. in molecular biology, Dr. Runge earned his M.D. from the Johns Hopkins School of Medicine, where he was an intern and resident in internal medicine. He then completed a cardiology fellowship at Harvard's Massachusetts General Hospital and was a faculty member there prior to moving to Emory University as an Associate Professor of Medicine in 1989. Before joining the UNC faculty in 2000, Dr. Runge held the John Sealy Distinguished Centennial Chair in Internal Medicine and was Director of the Division of Cardiology and the Sealy Center for Molecular Cardiology at the University of Texas Medical Branch at Galveston.

In addition to serving as a member of the Experimental Cardiovascular Sciences Study Section of the National Institutes of Health, Dr. Runge also has published over 150 peer-reviewed manuscripts and is a renowned leader in vascular biology.

About Lilly  
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. C-LLY

Refer to:  (317) 433-9899 – Edward Sagebiel

(Logo:  http://photos.prnewswire.com/prnh/20031219/LLYLOGO)

 


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ranbaxy kündigt Verbesserungen bei Geschäftsstandards und Qualitätssicherungsinitiativen an
2. CVBT-Aktionäre stimmen für Veränderungen
3. Marken startet erfolgreich Workshop-Reihe zu Qualitätsvereinbarungen
4. Remedy Informatics Cardiovascular Registry Selected by World-Renowned Cleveland Clinic Heart and Vascular Institute
5. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
6. Elsevier Selected as New Publisher of The American Journal of Geriatric Psychiatry
7. DICOM Grid Selected as a Finalist for the 2012 Red Herring Top 100 Americas Award
8. Centene Corporation Selected for Ohio Medicaid Contract
9. Bench Internationals Denise (DeeDee) DeMan Elected to SoCalBios Board of Directors
10. Sterne, Kessler, Goldstein & Fox Selected by 15 Year Old Winner of Intel International Science and Engineering Fair
11. Nature Made Selected As "Top Recommended Health Product" By U.S. News & World Report And Pharmacy Times
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017  Experts in the field ... devices like  Soberlink Systems  as a model for ... published in early 2017, concluded that remote blood ... managing patient recovery." The findings of ... Addiction Medicine, detail a range of variables that ...
(Date:3/29/2017)... , March 29, 2017  The leader in accelerated ... Drs. Sam Daher , Manal Ibrahim , ... David Couchat will be the featured microlecture presenters at ... American Association of Orthodontists (AAO) Annual Session, April 21-25, ... the microlectures beginning daily at 11:20 a.m. On the ...
(Date:3/29/2017)... N.J. , March 29, 2017  Glenmark ... results for GSP 301, an investigational fixed-dose combination ... (665 mcg) administered twice-daily as a nasal spray ... rhinitis. These results are from a recently completed ... of GSP 301 combination therapy versus mometasone, olopatadine ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... Dr. Angela Cotey, a noted general dentist ... new pediatric patients, with or without a referral. Dr. Cotey knows that interceptive ... outcome and experience. When patients receive early treatment, they may achieve straight teeth with ...
(Date:3/29/2017)... , ... March 29, 2017 , ... Curio Wellness ... to announce the finalization of the company’s executive management team with prominent executives from ... operations is Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who has more ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of ... and is touted to be the next revolution in our fight against this complex ... the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While ...
(Date:3/29/2017)... ... ... The Wharton School of the University of Pennsylvania is pleased to announce ... million gift to establish the Ken Moelis and Julie Taffet Moelis Advance Access ... MBA for highly-qualified Penn undergraduates whose academic and career interests expand traditional notions of ...
(Date:3/28/2017)... ... March 28, 2017 , ... Tuesday, March 28, 2017, ... public to take the Diabetes Risk Test to find out if they are at ... World Airports will light up the evening sky by programming the LAX pylons the ...
Breaking Medicine News(10 mins):